Key result
Young asymptomatic childhood cancer survivors treated with anthracyclines exhibited significantly lower peripheral vascular endothelial function (PAT-RHI 1.94 vs 2.23) compared to healthy controls.
Why the study?
Childhood cancer survivors are at increased risk for cardiovascular diseases, prompting evaluation of cardiac, carotid, lipid, and apolipoprotein measures in young adult survivors compared with healthy controls.
Does previous anthracycline treatment for childhood cancer alter cardiac, vascular, and metabolic parameters in young adulthood compared to healthy controls?
Population
53 childhood cancer survivors aged 20-30 years and 53 sex-matched controls
Comparison
Low vs high anthracycline dose childhood cancer survivors vs healthy controls
Authors
Loading...
Subclinical cardiac and vascular changes in asymptomatic young CCS support enhanced surveillance; leaves open whether targeted interventions modify long-term CVD risk.
Cross-Sectional (n=106)
Single-blind
No
Does previous anthracycline treatment for childhood cancer alter cardiac, vascular, and metabolic parameters in young adulthood compared to healthy controls?
Absolute Event Rate: 1.94% vs 2.23%
p-value: p=0.013
Young asymptomatic childhood cancer survivors exhibit early subclinical cardiac, vascular, and lipid changes that may increase their future risk of cardiovascular disease, highlighting the need for long-term cardiometabolic monitoring.
Broberg et al. (2021) conducted a cross-sectional in Childhood cancer survivors (n=106). Anthracycline treatment vs. Healthy controls was evaluated on Peripheral arterial tonometry-reactive hyperaemia index (PAT-RHI) (p=0.013). Young asymptomatic childhood cancer survivors treated with anthracyclines exhibited significantly lower peripheral vascular endothelial function (PAT-RHI 1.94 vs 2.23) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: